Show/Hide Menu

MOR209/ES414

MOR209/ES414 is a bi-specific anti-PSMA/anti-CD3 antibody against prostate cancer. The antibody is based on the ADAPTIRTM platform .

The immunotherapeutic protein activates the patients’ T cell immunity specifically against prostate cancer cells expressing Prostate Specific Membrane Antigen (PSMA), an antigen commonly overexpressed in this tumor. The anti-CD3 domains of the molecule selectively bind to the T cell receptor on cytotoxic T cells which become activated when the anti-PSMA domains crosslink them to the cancer cells. The two pairs of binding domains of MOR209/ES414 are linked to opposite ends of an immunoglobulin Fc domain to extend the half-life and enable the use of a purification process typical of lg-based molecules.

Mode of Action

Source: Emergent BioSolutions

Prostate cancer is the most common cancer in men with approximately 900,000 new cases annually worldwide, thereof 230,000 in the United States. Although screening, radiation, surgery and hormone ablation therapy have greatly improved the detection and treatment of early-stage prostate cancer, these new therapies only improve life expectancy by a few months for patients with metastatic castration-resistant prostate cancer. Preclinical in vitro and in vivo studies have shown that MOR209/ES414 redirects T cell cytotoxicity towards prostate cancer cells expressing PSMA, thus suggesting the potential to address this remaining unmet medical need.

Clinical Studies

MOR209/ES414 is currently being investigated in a clinical phase 1 study in metastatic, castration-resistant prostate cancer (mCRPC). Here you can find further information on the active clinical trial.

Background

MOR209/ES414 is part of MorphoSys’s collaboration with Emergent BioSolutions to jointly develop the compound. At the beginning of 2015, the companies initiated a phase 1 clinical trial evaluating the compound in patients with metastatic castration-resistant prostate cancer (mCRPC). On August 1, 2016 Emergent BioSolutions completed a spin-off named Aptevo Therapeutics. MOR209/ES414 is now part of this spin-off containing the company’s biosciences business.